Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity

被引:11
作者
Pogacar, Ziva [1 ]
Johnson, Jackie L. [1 ]
Krenning, Lenno [2 ]
De Conti, Giulia [1 ]
Jochems, Fleur [1 ]
Lieftink, Cor [3 ]
Velds, Arno [4 ]
Wardak, Leyma [1 ]
Groot, Kelvin [1 ]
Schepers, Arnout [1 ]
Wang, Liqin [1 ]
Song, Ji-Ying [5 ]
van de Ven, Marieke [6 ]
van Tellingen, Olaf [7 ]
Medema, Rene H. [2 ]
Beijersbergen, Roderick L. [1 ,3 ]
Bernards, Rene [1 ]
de Oliveira, Rodrigo Leite [1 ,8 ]
机构
[1] Netherlands Canc Inst, Oncode Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Oncode Inst, Div Cell Biol, Amsterdam, Netherlands
[3] Netherlands Canc Inst, NKI Robot & Screening Ctr, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Genom Core Facil, Amsterdam, Netherlands
[5] Netherlands Canc Inst, Div Anim Pathol, Amsterdam, Netherlands
[6] Netherlands Canc Inst, Mouse Clin Canc & Aging, Amsterdam, Netherlands
[7] Netherlands Canc Inst, Div Pharmacol, Amsterdam, Netherlands
[8] Univ Amsterdam, CRISPR Expertise Ctr, Canc Ctr Amsterdam, Med Ctr, Amsterdam, Netherlands
来源
PLOS ONE | 2022年 / 17卷 / 09期
基金
欧盟地平线“2020”; 欧洲研究理事会;
关键词
SULFONAMIDE ANTICANCER AGENT; CELL-CYCLE; PHASE-I; CDK4/6; INHIBITION; BREAST-CANCER; E7070; PHOSPHORYLATION; RESISTANCE; SCHEDULE; DECISION;
D O I
10.1371/journal.pone.0273182
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Inducing senescence in cancer cells is emerging as a new therapeutic strategy. In order to find ways to enhance senescence induction by palbociclib, a CDK4/6 inhibitor approved for treatment of metastatic breast cancer, we performed functional genetic screens in palbociclib-resistant cells. Using this approach, we found that loss of CDK2 results in strong senescence induction in palbociclib-treated cells. Treatment with the CDK2 inhibitor indisulam, which phenocopies genetic CDK2 inactivation, led to sustained senescence induction when combined with palbociclib in various cell lines and lung cancer xenografts. Treating cells with indisulam led to downregulation of cyclin H, which prevented CDK2 activation. Combined treatment with palbociclib and indisulam induced a senescence program and sensitized cells to senolytic therapy. Our data indicate that inhibition of CDK2 through indisulam treatment can enhance senescence induction by CDK4/6 inhibition.
引用
收藏
页数:23
相关论文
共 65 条
[1]   REGULATION OF THE RETINOBLASTOMA PROTEIN-RELATED P107 BY G(1) CYCLIN COMPLEXES [J].
BEIJERSBERGEN, RL ;
CARLEE, L ;
KERKHOVEN, RM ;
BERNARDS, R .
GENES & DEVELOPMENT, 1995, 9 (11) :1340-1353
[2]   Transcriptome signature of cellular senescence (vol 47, pg 7294, 2019) [J].
Casella, Gabriel ;
Munk, Rachel ;
Kim, Kyoung Mi ;
Piao, Yulan ;
De, Supriyo ;
Abdelmohsen, Kotb ;
Gorospe, Myriam .
NUCLEIC ACIDS RESEARCH, 2019, 47 (21) :11476-11476
[3]   Enrichr: interactive and collaborative HTML']HTML5 gene list enrichment analysis tool [J].
Chen, Edward Y. ;
Tan, Christopher M. ;
Kou, Yan ;
Duan, Qiaonan ;
Wang, Zichen ;
Meirelles, Gabriela Vaz ;
Clark, Neil R. ;
Ma'ayan, Avi .
BMC BIOINFORMATICS, 2013, 14
[4]   Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation [J].
Clurman, BE ;
Sheaff, RJ ;
Thress, K ;
Groudine, M ;
Roberts, JM .
GENES & DEVELOPMENT, 1996, 10 (16) :1979-1990
[5]  
Dittrich C, 2003, CLIN CANCER RES, V9, P5195
[6]   CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes [J].
Evers, Bastiaan ;
Jastrzebski, Katarzyna ;
Heijmans, Jeroen P. M. ;
Grernrum, Wipawadee ;
Beijersbergen, Roderick L. ;
Bernards, Rene .
NATURE BIOTECHNOLOGY, 2016, 34 (06) :631-633
[7]   Therapy-Induced Senescence in Cancer [J].
Ewald, Jonathan A. ;
Desotelle, Joshua A. ;
Wilding, George ;
Jarrard, David F. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (20) :1536-1546
[8]   Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition [J].
Fassl, Anne ;
Brain, Christopher ;
Abu-Remaileh, Monther ;
Stukan, Iga ;
Butter, Deborah ;
Stepien, Piotr ;
Feit, Avery S. ;
Bergholz, Johann ;
Michowski, Wojciech ;
Otto, Tobias ;
Sheng, Qing ;
Loo, Alice ;
Michael, Walter ;
Tiedt, Ralph ;
DeAngelis, Carmine ;
Schiff, Rachel ;
Jiang, Baishan ;
Jovanovic, Bojana ;
Nowak, Karolina ;
Ericsson, Maria ;
Cameron, Michael ;
Gray, Nathanael ;
Dillon, Deborah ;
Zhao, Jean J. ;
Sabatini, David M. ;
Jeselsohn, Rinath ;
Brown, Myles ;
Polyak, Kornelia ;
Sicinski, Piotr .
SCIENCE ADVANCES, 2020, 6 (25)
[9]   PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro [J].
Finn, Richard S. ;
Dering, Judy ;
Conklin, Dylan ;
Kalous, Ondrej ;
Cohen, David J. ;
Desai, Amrita J. ;
Ginther, Charles ;
Atefi, Mohammad ;
Chen, Isan ;
Fowst, Camilla ;
Los, Gerret ;
Slamon, Dennis J. .
BREAST CANCER RESEARCH, 2009, 11 (05)
[10]   Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor [J].
Freeman-Cook, Kevin ;
Hoffman, Robert ;
Miller, Nichol ;
Almaden, Jonathan ;
Chionis, John ;
Zhang, Qin ;
Eisele, Koleen ;
Liu, Chaoting ;
Zhang, Cathy ;
Huser, Nanni ;
Nguyen, Lisa ;
Costa-Jones, Cinthia ;
Niessen, Sherry ;
Carelli, Jordan ;
Lapek, John ;
Weinrich, Scott ;
Wei, Ping ;
McMillan, Elizabeth ;
Wilson, Elizabeth ;
Wang, Tim ;
McTigue, Michele ;
Ferre, Rose ;
He, You-Ai ;
Ninkovic, Sacha ;
Behenna, Douglas ;
Tran, Khanh ;
Sutton, Scott ;
Nagata, Asako ;
Ornelas, Martha ;
Kephart, Susan ;
Zehnder, Luke ;
Murray, Brion ;
Xu, Meirong ;
Solowiej, James ;
Visswanathan, Ravi ;
Boras, Britton ;
Looper, David ;
Lee, Nathan ;
Bienkowska, Jadwiga ;
Zhu, Zhou ;
Kan, Zhengyan ;
Ding, Ying ;
Mu, Xinmeng ;
Oderup, Cecilia ;
Salek-Ardakani, Shahram ;
White, Michael ;
VanArsdale, Todd ;
Dann, Stephen .
CANCER CELL, 2021, 39 (10) :1404-+